Teva’s thrice-weekly Copaxone is priced at about a 10% discount to regular (daily) Copaxone, according to MNTA’s CFO, Rick Shea on today's Leerink webcast. (This differs from the prior unconfirmed report that the discount was 2%.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.